Allogeneic transplant recipients are at high risk of developing secondary malignancies as a late complication of therapy. We report a case of essential thrombocythemia occurring 8 years following bone marrow transplantation (BMT) for chronic myelogenous leukemia. Keywords: essential thrombocythemia; marrow transplantation; long-term complication Allogeneic bone marrow transplantation (BMT) is a frequently used and efficacious therapeutic modality for selected hematologic malignancies. However, development of secondary neoplasms following BMT is emerging as a serious late complication for long-term survivors.
acute or a chronic inflammatory disorder was found. Hemoglobin was 15.2 g/l and white blood count was 8900/mm 3 , of which 70% were neutrophils and 22% were lymphocytes. Basophils and a leukoerythroblastic picture were not observed on the peripheral blood smear, but large platelets were present. Serum ferritin was normal. Platelet aggregation studies revealed reduced platelet response to collagen, ADP and arachidonic acid, and complete absence of aggregation with epinephrine stimulation. With an enzyme immunoassay using polyclonal antibodies raised against recombinant human thrombopoietin (TPO) for capture and signal generation (material kindly provided by Amgen, Thousand Oaks, CA, USA), endogenous TPO level was 208 pg/ml (serum TPO levels from 90 normal controls: 51-407 pg/ml). Computerized tomography of the chest, abdomen and pelvis were normal.
Bone marrow aspirate and core biopsy showed a normocellular marrow with increased megakaryocytes. Karyotypic analysis of 16 metaphases was normal (46,XY). The bcr/abl fusion cDNA was not detected by nested reversetranscriptase polymerase chain reaction performed as previously described. 3 Granulomas and fibrosis were absent, and cultures were sterile. Stainable iron was present.
To assess hematopoietic chimerism, genomic DNA was isolated, digested with HinfI restriction endonuclease and subjected to agarose gel electrophoresis. HinfI-digested DNA was then transferred to a nylon membrane (ZetaProbe, BioRad, Hercules, CA, USA), and hybridized to radiolabelled hypervariable minisatellite repeat probe D1S7. 4 Filters were exposed to X-ray film and developed. The variable number of tandem repeat (VNTR) patterns of the recipient (lanes 1 and 3) and the donor (lane 2) are shown in Figure 1 . The disappearance of recipient-specific bands A and C (lane 3) at 8 years after BMT suggested that all cells were of donor origin. Sensitivity of current VNTR analysis was 1-5%.
Notably, the donor is a healthy 40-year-old man with no previous medical problems. Physical examination revealed no splenomegaly, and routine laboratory tests and complete blood count were unremarkable. The donor's platelet count was 384 000/mm 3 . 
Essential thrombocythemia following BMT

Discussion
Secondary malignancies are reported as late complications of BMT, with an 11-fold increased risk over that of a comparable normal population. 2 The incidence of chronic myeloproliferative disorders after BMT is unknown, but appears to be rare. Marmont et al 5 reported a case of Philadelphia chromosome positive leukemic relapse in donor cells after allogeneic BMT for Philadelphia chromosome positive CML. To our knowledge, this represents the first report of a transplant patient who developed essential thrombocythemia after allogeneic BMT. Known causes of reactive thrombocytosis and other myeloproliferative disorders were excluded. The diagnosis was further supported by the presence of increased megakaryocytes in the bone marrow, results of platelet aggregation studies, and the absence of the Philadelphia chromosome.
It is of interest that the serum TPO levels were not suppressed in this patient despite a markedly elevated platelet count. It has been proposed, based on TPO levels in patients with aplastic anemia and idiopathic thrombocytopenic purpura, that the serum TPO levels were inversely correlated with total platelet mass. 6 This case illustrates a dysregulation in the relationship between platelet mass and serum TPO levels, and is consistent with observations reported in patients with essential thrombocytopenia, 7, 8 suggesting a neoplastic disorder driven by dysregulated TPO production. No relationship between TPO levels and the platelet count was observed in patients with other myeloproliferative disorders. 8 The origin of the neoplastic clone in post-transplant malignancies has been determined by different methods, including white blood cell isoenzyme polymorphisms, routine and multi-parameter fluorescence in situ hybridization (FISH) karyotypic analyses, 9 and DNA polymorphisms recognized by restriction endonuclease digestion and Southern blot hybridization or polymerase chain reaction analyses. 10 The identification of a highly polymorphic genetic locus in the human genome makes it possible to distinguish individual genotypes. Identification of the origin of the malignant clone, in this case, was confounded by the low relative proportion of megakaryocytes in the bone marrow cell population and the technical limitations in obtaining a homogenous tumor sample for analysis. Although we cannot exclude the possibility that the origin of the abnormal clone is recipient-derived, the available data suggest that it originated from the donor cells. Nevertheless, the donor remains healthy 8 years after marrow collection.
Essential thrombocythemia is a clonal disorder of unknown etiology, originating in a pluripotent stem cell. In vitro data suggest that the proto-oncogene c-mpl exerts an important role in the growth of megakaryocyte precursors and in the cytokine-independent megakaryocytopoiesis seen in patients with various myeloproliferative disorders. 11 It is possible that c-mpl may play a role in the pathogenesis of essential thrombocythemia. Pathophysiologic mechanisms implicated in the development of secondary malignancies post-BMT are not well understood. Potential mechanisms include abnormalities in the marrow microenvironment of the recipient and the passive transfer of dominant oncogenes from recipient to donor cells after transplantation. 12 Radiation, chemotherapy, immunosuppression, chronic antigen stimulation (GVHD) and the original disease for which transplantation was performed are predisposing factors.
